SCHEMBL7069211

SCHEMBL7069211

O=C(c1cccc(O)c1)N1CCOCC1

nearest known ligand 0.71

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.71
MGLL Q99685 3/20 0.64
L3MBTL1 Q9Y468 1/20 0.64
KDM4E B2RXH2 1/20 0.62
TSHR P16473 2/20 0.61
RECQL P46063 1/20 0.61
ALDH1A1 P00352 2/20 0.59
PKM P14618 1/20 0.58
ERN1 O75460 1/20 0.58
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
NPC1 O15118 1/20 0.57
TP53 P04637 1/20 0.57
MAPK1 P28482 1/20 0.57
RAB9A P51151 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30957421 1.00 HPGD (0.71) HPGDMGLLL3MBTL1KDM4ETSHR
SCHEMBL10720509 0.90 L3MBTL1 (0.71) HPGDL3MBTL1KDM4ETSHRRECQL
Phenol SCHEMBL28280794 0.85 HPGD (0.76) HPGDL3MBTL1TSHRALDH1A1KMT2A
SCHEMBL28294867 0.85 HPGD (0.71) HPGDL3MBTL1KDM4ETSHRRECQL
SCHEMBL2644377 0.84 HPGD (0.67) HPGDMGLLL3MBTL1ALDH1A1MEN1
SCHEMBL15605882 0.84 SMN1; SMN2 (0.65) HPGDMGLLALDH1A1MEN1KMT2A
SCHEMBL30577960 0.83 L3MBTL1 (0.64) HPGDL3MBTL1KDM4ETSHRRECQL
SCHEMBL1199986 0.83 L3MBTL1 (0.64) HPGDL3MBTL1KDM4ETSHRRECQL
SCHEMBL28860346 0.83 HPGD (1.00) HPGDL3MBTL1KDM4ETSHRRECQL
SCHEMBL30957287 0.83 HPGD (0.68) HPGDMGLLALDH1A1ERN1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026749-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2025-01-23 US disclosed
US-12060349-B2 Glucosylceramide synthase inhibitors GENZYME CORPORATION (US) 2024-08-13 US disclosed
EP-4098654-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS Genzyme Corporation (US) 2022-12-07 EP disclosed
CN-114533729-A Glucosylceramide synthase inhibitors 建新公司 2022-05-27 CN disclosed
US-20220073508-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2022-03-10 US disclosed
EP-2895484-B1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORP (US) 2022-02-23 EP disclosed
CN-108864076-B Glucosylceramide synthase inhibitors 建新公司 2022-02-11 CN disclosed
CN-109456704-B Metal Chemical Mechanical Planarization (CMP) compositions and methods thereof 弗萨姆材料美国有限责任公司 2021-08-27 CN disclosed
US-11008316-B2 Glucosylceramide synthase inhibitors GENZYME CORPORATION (US) 2021-05-18 US disclosed
US-10920106-B2 Metal chemical mechanical planarization (CMP) composition and methods therefore VERSUM MATERIALS US, LLC (US) 2021-02-16 US disclosed
WO-2016198374-A1 AROMATIC SULFONAMIDE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-12-15 WO disclosed
WO-2016068580-A2 NOVEL PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATING THE CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS) DONG-A SOCIO HOLDINGS CO., LTD. (KR) 2016-05-06 WO disclosed
US-20160122343-A1 Novel Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs) DONG-A ST CO., LTD. (KR) 2016-05-05 US disclosed
US-20150210681-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2015-07-30 US disclosed
EP-2895484-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS Genzyme Corporation (US) 2015-07-22 EP disclosed
WO-2014043068-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2014-03-20 WO disclosed
WO-2003047572-A1 USE OF 1-PHENYL-OXAZOLIDINE-2-ONE COMPOUNDS AS PROTEASE M INHIBITORS MERCK PATENT GMBH (DE) 2003-06-12 WO disclosed
US-6329502-B1 VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS; TREATMENT OF AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) JAPAN ENERGY CORPORATION (JP) 2001-12-11 US disclosed
US-6313094-B1 COMPOSITION FOR INHIBITING HUMAN IMMUNODEFICIENCY VIRUS REPLICATION JAPAN ENERGY CORPORATION (JP) 2001-11-06 US disclosed
EP-0490667-B1 HIV protease inhibitors JAPAN ENERGY CORP (JP) 1999-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210681-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA HPGD 1041/4885MGLL 118/4885L3MBTL1 1688/4885
US-11008316-B2 Glucosylceramide synthase inhibitors GBA1, GBA2, GAA HPGD 1057/4885MGLL 129/4885L3MBTL1 2336/4885
US-12060349-B2 Glucosylceramide synthase inhibitors GBA1, GBA2, GALC HPGD 1298/4885MGLL 156/4885L3MBTL1 3424/4885
US-20250026749-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA HPGD 1041/4885MGLL 118/4885L3MBTL1 1688/4885
US-20160122343-A1 Novel Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs) KDM1B, KDM1A, KDM3B HPGD 1492/4885MGLL 3246/4885L3MBTL1 1892/4885
US-20220073508-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA HPGD 1041/4885MGLL 118/4885L3MBTL1 1688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.